| Literature DB >> 22228991 |
Anna Hedlund1, Maria Ahrén, Håkan Gustafsson, Natalia Abrikossova, Marcel Warntjes, Jan-Ingvar Jönsson, Kajsa Uvdal, Maria Engström.
Abstract
As the utility of magnetic resonance imaging (MRI) broadens, the importance of having specific and efficient contrast agents increases and in recent time there has been a huge development in the fields of molecular imaging and intracellular markers. Previous studies have shown that gadolinium oxide (Gd(2)O(3)) nanoparticles generate higher relaxivity than currently available Gd chelates: In addition, the Gd(2)O(3) nanoparticles have promising properties for MRI cell tracking. The aim of the present work was to study cell labeling with Gd(2)O(3) nanoparticles in hematopoietic cells and to improve techniques for monitoring hematopoietic stem cell migration by MRI. Particle uptake was studied in two cell lines: the hematopoietic progenitor cell line Ba/F3 and the monocytic cell line THP-1. Cells were incubated with Gd(2)O(3) nanoparticles and it was investigated whether the transfection agent protamine sulfate increased the particle uptake. Treated cells were examined by electron microscopy and MRI, and analyzed for particle content by inductively coupled plasma sector field mass spectrometry. Results showed that particles were intracellular, however, sparsely in Ba/F3. The relaxation times were shortened with increasing particle concentration. Relaxivities, r(1) and r(2) at 1.5 T and 21°C, for Gd(2)O(3) nanoparticles in different cell samples were 3.6-5.3 s(-1) mM(-1) and 9.6-17.2 s(-1) mM(-1), respectively. Protamine sulfate treatment increased the uptake in both Ba/F3 cells and THP-1 cells. However, the increased uptake did not increase the relaxation rate for THP-1 as for Ba/F3, probably due to aggregation and/or saturation effects. Viability of treated cells was not significantly decreased and thus, it was concluded that the use of Gd(2)O(3) nanoparticles is suitable for this type of cell labeling by means of detecting and monitoring hematopoietic cells. In conclusion, Gd(2)O(3) nanoparticles are a promising material to achieve positive intracellular MRI contrast; however, further particle development needs to be performed.Entities:
Keywords: Ba/F3 cells; THP-1 cells; cell labeling; contrast agent; gadolinium oxide; magnetic resonance imaging
Mesh:
Substances:
Year: 2011 PMID: 22228991 PMCID: PMC3252671 DOI: 10.2147/IJN.S23940
Source DB: PubMed Journal: Int J Nanomedicine ISSN: 1176-9114
Ba/F3 cells incubated in 2 mM gadolinium compared to nontreated cells
| 2 mM gadolinium + protamine sulfate | 2 mM gadolinium − protamine sulfate | Control + protamine sulfate | Control − protamine sulfate | |
|---|---|---|---|---|
| 24 hours of incubation | 72% ± 5% | 73% ± 7% | 77% ± 5% | 75% ± 6% |
| 48 hours of incubation | 70% ± 7% | 72% ± 11% | 81% ± 6% | 70% ± 4% |
| 72 hours of incubation | 73% ± 3% | 68% ± 5% | 83% ± 7% | 75% ± 7% |
Notes: Cells were also exposed or not exposed to transfection agent protamine sulfate. Figures in the table show percentages of viable cells.
Figure 1Representative image of THP-1 cell treated with 2.0 mM gadolinium shows several vacuoles containing gadolinium oxide nanoparticles and invaginations at the cell surface indicating phagocytic processes (left panel). Illustration of the phagocytic process: (1) nanoparticles in the extracellular fluid, (2) nanoparticles approaching the cell surface, (3) nanoparticles at the cell surface, and (4) nanoparticles internalized in cell vacuole (right panel).
Figure 2Representative electron microscopy images of cells: THP-1 in (A) and (B); Ba/F3 in (C) and (D). (A) and (C) show gadolinium oxide incubated cells (treated with protamine sulfate and 2.0 mM gadolinium). Gadolinium oxide nanoparticles are visible inside vacuoles of the cell. Images (B) and (D) show control cells not treated at all. These cells do not have as many vacuoles indicating that they were not phagocytically active.
Figure 3Ba/F3 cells with gadolinium oxide nanoparticles on cell surface. Small endocytic invaginations (see inset) indicate a possible internalization process.
Figure 4Relaxation of gadolinium oxide nanoparticles in THP-1 and Ba/F3 cells. Samples were either treated with protamine sulfate or not and the cells were incubated with gadolinium oxide nanoparticles in two different gadolinium concentrations for each sample (0.5 mM or 2.0 mM).
Abbreviations: conc, concentration; Gd, gadolinium.
Relaxivity values r1 and r2 (s−1 mM−1) at 1.5 T and 21°C for Ba/F3 and THP-1 cell samples incubated with gadolinium oxide nanoparticles with or without protamine sulfate treatment
| r1 | r2 | r2/r1 | |
|---|---|---|---|
| Ba/F3 + protamine sulfate | 5.3 ± 0.5 | 17.2 ± 1.3 | 3.2 |
| Ba/F3 − protamine sulfate | 4.5 ± 0.5 | 13.4 ± 1.0 | 3.0 |
| THP-1 + protamine sulfate | 3.6 ± 0.3 | 9.6 ± 0.9 | 2.7 |
| THP-1 − protamine sulfate | 4.7 ± 0.8 | 13.6 ± 1.0 | 2.9 |
Note: Relaxivity calculations were based on gadolinium concentration in cells after treatment.
Figure 5Upper panel shows signal intensity of incubated cell samples (repetition time = 1000 milliseconds, echo time = 20 milliseconds). The first row is Ba/F3 and the second row is THP-1. Columns labeled “high” are treated with 2.0 mM gadolinium and “low” with 0.5 mM gadolinium. Columns labeled with “+” are protamine sulfate treated and with “−” are not treated with protamine sulfate. The rightmost samples (labeled C) are cell control samples with no particles. Sample labeled R is Gd-diethylene triamine pentacetic acid reference (0.1 mM gadolinium in water). Bottom panel shows corresponding T1 map, which shows different colors corresponding to different T1 times.